CD274 and neoplasm: Immune checkpoint inhibitors (ICIs), especially anti-PD-1/PD-L1 antibodies, block tumor immune evasion mechanisms and re-activate the immune system to recognize and eliminate tumor cells, achieving groundbreaking success in melanoma therapy [1–3].